Evidence map›Paper›PMID 38707709›Full record

ArticleBrain communications2024

Testing of putative antiseizure medications in a preclinical Dravet syndrome zebrafish model.

Paige A Whyte-Fagundes, Anjelica Vance, Aloe Carroll, Francisco Figueroa, Catherine Manukyan, Scott C Baraban

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Reflections on the Brain Conference 2024.Brain communications · 2024
    Article
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Paige A Whyte-FagundesEpilepsy Research Laboratory and Weill Institute for Neuroscience, Department of Neurological Surgery, University of California San Francisco, San Francisco, CA 94143, USA.ORCID https://orcid.org/0000-0003-4878-9955
Anjelica VanceEpilepsy Research Laboratory and Weill Institute for Neuroscience, Department of Neurological Surgery, University of California San Francisco, San Francisco, CA 94143, USA.
Aloe CarrollBehavioral Neurosciences, Northeastern University, Boston, MA 02115, USA.
Francisco FigueroaEpilepsy Research Laboratory and Weill Institute for Neuroscience, Department of Neurological Surgery, University of California San Francisco, San Francisco, CA 94143, USA.
Catherine ManukyanHelen Wills Neuroscience Institute, University of California, Berkeley, CA 94720, USA.
Scott C BarabanEpilepsy Research Laboratory and Weill Institute for Neuroscience, Department of Neurological Surgery, University of California San Francisco, San Francisco, CA 94143, USA.ORCID https://orcid.org/0000-0003-1975-9781

Funding

ZEBRAFISH MODELS FOR DRAVET SYNDROME RESEARCH AND DISCOVERYR01NS096976 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BARABAN, SCOTT C · 2016 to 2024
$3.9M
Gluconeogenic control of Dravet SyndromeR01HD102071 · NICHD · UNIVERSITY OF COLORADO DENVER · PI BARABAN, SCOTT C, PATEL, MANISHA N · 2020 to 2024
$2.5M
NICHD NIH HHS R01 HD102071NINDS NIH HHS R01 NS096976
6 · The paper itself

Abstract

Dravet syndrome is a severe genetic epilepsy primarily caused by

Indexed as

anti-seizure medicationsdravetdrug screeningepilepsyzebrafish larvae

Identifiers

PMID38707709
PMCPMC11069116

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.